OASIS

The OASIS data are distributed to the greater scientific community under the following terms:

1. You will not attempt to establish the identity of or make contact with any of the human participants included in the OASIS data. This includes, but is not limited to, facial recognition and 3D facial rendering.

2. You will acknowledge the use of OASIS data and data derived from OASIS data when publicly presenting any results or algorithms that benefitted from their use. All papers, book chapters, books, posters, oral presentations, and other printed and digital presentations of results derived from OASIS data should contain the following:

a. Acknowledgments: "Data provided [in part] by OASIS [insert appropriate OASIS source info]”

i. OASIS-1: Cross-Sectional: Principal Investigators: D. Marcus, R, Buckner, J, Csernansky J. Morris; P50 AG05681, P01 AG03991, P01 AG026276, R01 AG021910, P20 MH071616, U24 RR021382

ii. OASIS-2: Longitudinal: Principal Investigators: D. Marcus, R, Buckner, J. Csernansky, J. Morris; P50 AG05681, P01 AG03991, P01 AG026276, R01 AG021910, P20 MH071616, U24 RR021382

iii. OASIS-3: Longitudinal Multimodal Neuroimaging: Principal Investigators: T. Benzinger, D. Marcus, J. Morris; NIH P30 AG066444, P50 AG00561, P30 NS09857781, P01 AG026276, P01 AG003991, R01 AG043434, UL1 TR000448, R01 EB009352. AV-45 doses were provided by Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly.

iv. OASIS-3_AV1451: Principal Investigators: T. Benzinger, J. Morris; NIH P30 AG066444, AW00006993. AV-1451 doses were provided by Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly.

v. OASIS-4: Clinical Cohort: Principal Investigators: T. Benzinger, L. Koenig, P. LaMontagne

b. Citation: The specific publications that are appropriate to cite in any given study will depend on what OASIS data were used and for what purposes. An annotated and current list of OASIS publications is available at http://www.oasis-brains.org.

i. OASIS-1: Cross-Sectional: https://doi.org/10.1162/jocn.2007.19.9.1498

ii. OASIS-2: Longitudinal: https://doi.org/10.1162/jocn.2009.21407

iii. OASIS-3: Longitudinal Multimodal Neuroimaging: https://doi.org/10.1101/2019.12.13.19014902

iv. OASIS-4: Clinical Cohort: https://doi.org/10.1016/j.nicl.2020.102248

c. All proposed publications or presentations using Florbetapir F18 (AV45) or Flortaucipir F18 (AV1451) PET data must be submitted to Avid Radiopharmaceuticals for review and comment thirty days prior to such presentation or publication for review of intellectual property interests. See Imaging data dictionary for contact information and details.

3. You agree to provide the Knight ADRC upon request with information on your use of OASIS data.

4. Failure to abide by these data use terms may result in termination of your right to access and use OASIS data.